https://www.thebodypro.com/category/truvada-pro

Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada)

The Latest

doctor talking to unrecognizable patient
Conference Coverage

For PrEP to Work, Shared Doctor-Patient Decision-Making Is Key

The process of choosing between PrEP options is often not straightforward. Oni Blackstock, M.D., explains how providers can help ensure their patients end up with the most successful option for them.

By Terri Wilder, M.S.W.
Hep C virus
News

This Week in HIV Research: Hep C, That Other Epidemic Within an Epidemic

Sept. 3, 2020: A hepatitis C microelimination program for people living with HIV; PrEP concentrations and gender-affirming hormones; a collaborative intervention to improve opioid prescribing practices; TDF and fracture risk.

By Barbara Jungwirth and Myles Helfand
Truvada
News

New Study Shows Effectiveness of On-Demand PrEP

Kaiser Permanente’s 2-1-1 pre-exposure prophylaxis (PrEP) program shows event-driven dosing works.

By Larry Buhl
raising the bar
News

This Week in HIV Research: Setting a New Bar

June 11, 2020: Diagnosis rates within a year of infection; rates of intentional non-daily PrEP use; neurological development in children of birth parents with HIV; point-of-care urine test to assess tenofovir levels.

By Barbara Jungwirth and Myles Helfand
cisgender woman prescription
Interviews

Evaluating PrEP Uptake and Adherence in Cisgender Women—and What to Do About It

Two researchers discuss their analysis of Philadelphia FIGHT’s HIV pre-exposure prophylaxis (PrEP) program for cisgender women.

By Terri Wilder, M.S.W.
Gilead headquarters
News

PrEP Advocates Call New Gilead Patent Suit Against HHS a ‘Distraction’

The drug manufacturer alleges the federal government filed for the Truvada prevention patent without their knowledge.

By Larry Buhl
pill bottles and cash
Conference Coverage

A PrEP Pricing Pickle: Descovy Will Need a Drastic Discount to Be Worthwhile, Study Finds

With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.

By Myles Helfand
Peter Staley Brenda Emily Goodrow and Mark Lemley credit Ivy Arce
Interviews

Oral Arguments in Antitrust Case Against HIV Drug Companies Began Last Week. Plaintiff Peter Staley Explains the Case

The case could change the way pharma companies make agreements to keep generic versions of single-tablet pills at bay.

By Terri Wilder, M.S.W.
Senior woman receives prescription medication from doctor
News Analysis

Should All PrEP Users on Truvada Switch to Descovy? These Leading Docs Say, ‘Not So Fast.’

Many fear the push to put more people on the new brand-name drug before Truvada goes generic this year.

By Larry Buhl
long winding road through countryside
News

This Week in HIV Research: The Long Road to the End

Dec. 12, 2019: A lot of catchup to do before “Ending the HIV Epidemic”; the value of online HIV self-test distribution; viral suppression is about more than basic HIV treatment services; effect of hormone therapy on PrEP levels.

By Barbara Jungwirth and Myles Helfand